PMID- 30005719
OWN - NLM
STAT- MEDLINE
DCOM- 20190827
LR  - 20210217
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 27
IP  - 5
DP  - 2019 May 7
TI  - Efficacy and Safety of CalliSpheres((R)) Drug-Eluting Beads Transarterial 
      Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients.
PG  - 565-573
LID - 10.3727/096504018X15313896322888 [doi]
AB  - This study aimed to investigate the efficacy and safety of drug-eluting beads 
      transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver 
      Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C 
      liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients 
      achieved complete response (CR) and partial response (PR) to give an overall 
      objective response rate (ORR) of 66.7%. With respect to the second cycle of 
      therapy, the ORR was higher in patients receiving DEB-TACE compared with those 
      receiving cTACE (57.1% vs. 11.1%). After the first cycle of DEB-TACE treatment, 
      the percentages of abnormal albumin (ALB), total protein (TP), total bilirubin 
      (TBIL), and alanine aminotransferase (ALT) worsened at 1 week and recovered at 1 
      month. The number of patients with abnormal aspartate aminotransferase (AST) did 
      not increase at 1 week but elevated at 1 month. After the second cycle of 
      DEB-TACE or cTACE treatment, no difference was observed between cTACE and 
      DEB-TACE in terms of all adverse events (AEs) at all visits, and most of the AEs 
      did not change after the second cycle in both groups. The most common AEs after 
      the first and second treatment cycles were pain, fever, and nausea/vomiting. 
      These results demonstrate that DEB-TACE offers patients with BCLC stage C liver 
      cancer a clinically active short-term treatment that is safe and relatively well 
      tolerated.
FAU - Liu, Yaohong
AU  - Liu Y
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Huang, Wensou
AU  - Huang W
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - He, Mingji
AU  - He M
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Lian, Hui
AU  - Lian H
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Guo, Yongjian
AU  - Guo Y
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Huang, Jingjun
AU  - Huang J
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Zhou, Jingwen
AU  - Zhou J
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
FAU - Zhu, Kangshun
AU  - Zhu K
AD  - Department of Minimally Invasive Interventional Radiology, The Second Affiliated 
      Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20180713
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Antineoplastic Agents)
RN  - 80168379AG (Doxorubicin)
RN  - D58G680W0G (pirarubicin)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Antineoplastic Agents/*therapeutic use
MH  - Aspartate Aminotransferases/blood
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - *Chemoembolization, Therapeutic
MH  - Doxorubicin/*analogs & derivatives/*therapeutic use
MH  - Drug Delivery Systems
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*drug therapy
MH  - Male
MH  - *Microspheres
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Treatment Outcome
PMC - PMC7848450
COIS- The authors declare no conflicts of interest.
EDAT- 2018/07/15 06:00
MHDA- 2019/08/28 06:00
PMCR- 2019/05/07
CRDT- 2018/07/15 06:00
PHST- 2018/07/15 06:00 [pubmed]
PHST- 2019/08/28 06:00 [medline]
PHST- 2018/07/15 06:00 [entrez]
PHST- 2019/05/07 00:00 [pmc-release]
AID - OR1329 [pii]
AID - 10.3727/096504018X15313896322888 [doi]
PST - ppublish
SO  - Oncol Res. 2019 May 7;27(5):565-573. doi: 10.3727/096504018X15313896322888. Epub 
      2018 Jul 13.